Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. is viewed positively due to its attractive current valuation and significant upside potential indicated by recent NPV analysis revisions. The company reported encouraging interim analysis results from its clinical studies, suggesting a 6-month potential improvement in median overall survival for patients treated with RenovoGem. Additionally, the planned commercialization of RenovoCath and anticipated positive clinical data in 2025 are expected to serve as strong catalysts for the company's stock performance.

Bears say

RenovoRx Inc reported a net loss of $2.4 million and an earnings per share (EPS) of $(0.10), slightly ahead of the analyst estimates but still indicative of ongoing financial challenges. The company operates in a high-risk sector, focusing on pancreatic cancer treatment, which has the lowest 5-year overall survival rate at 12%, underscoring significant unmet medical needs and poor patient outcomes. Despite potential growth prospects, the combination of persistent net losses and the daunting landscape of pancreatic cancer therapy presents substantial concerns regarding the company's financial sustainability and market position.

RenovoRx (RNXT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.